

Remarks

In the Office Action dated 29 December 2009, the Examiner objected to the Specification as allegedly failing to provide an appropriate cross-reference to related applications. Applicants respectfully submit that the 371 national phase transmittal for the present application specifically requested amendment of the present specification to include such cross-reference as required under 37 CFR 1.78. Nonetheless, in order to expedite prosecution of the case, Applicants have provided an amendment to the specification herein which cross-references the related applications. Entry of the present amendment to the specification is courteously requested.

Claim 12 was objected to by the Examiner as being informal for failing to conclude with a period. Applicants have made the appropriate correction to Claim 12 with the present amendment. Entry of said amendment is courteously requested.

The Office Action dated 29 December 2009 also contained a Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And / Or Amino Acid Sequence Disclosures. Applicants have responded to said Notice To Comply in a separate submission.

Applicants respectfully submit that the amendments submitted herein do not encompass added matter and courteously request entry of the present amendments and reconsideration of the present application.

Respectfully submitted,

/Alexander Wilson/  
Alexander Wilson  
Attorney for Applicants  
Registration No. 45,782  
Phone: 317-276-9477

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

March 29, 2010